source
- Scancell to merge into Neuphoria and seek $89 million equity as AstraZeneca's breast cancer drug gains EU approvalScancell announced it will merge into Neuphoria Therapeutics, taking over Neuphoria's Nasdaq listing ($NEUP) and planning to change the ticker to SCLT. The combined entity aims to raise up to $89 m…
- Biogen looks to Apellis acquisition to boost lagging Leqembi salesBiogen CEO Chris Viehbacher said the company's Alzheimer's drug Leqembi has underperformed since its 2023 launch. The drug, co-developed with Eisai, has struggled to meet sales expectations, promp…